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 Copyrighta bDavid T. Dunn and David V. GliddenPurpose of review
We discuss selected statistical issues in the design and analysis of preexposure prophylaxis (PrEP) trials.
The general principles may inform thinking for other interventions in HIV prevention.
Recent findings
To date, four different designs have been used to determine the effectiveness of PrEP: randomized, double-
blind, placebo-controlled; randomized, open-label, immediate or delayed access; nonrandomized
comparison of HIV incidence according to the level of drug detected; comparison of the observed HIV
incidence to the expected rate using historical control data. Open-label trials of PrEP, which assess public
health effectiveness, complement the placebo-controlled trials which established the biological efficacy of
TDF/ FTC. Future trials of PrEP will be highly challenging to design since a no PrEP group is difficult to
justify and the natural control regimen, TDF/FTC, is highly efficacious.
Summary
Standard statistical paradigms for noninferiority trials should be reconsidered for evaluating alternative PrEP
regimens.
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Randomized controlled trials of preexposure pro-
phylaxis (PrEP) have given rise to specific statistical
challenges both in design and analysis. In this article
we focus in depth on three issues: assessing the
influence of risk compensation, dealing with
patients with acute HIV infection at study enrol-
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placebo-controlled trials
‘Risk compensation’ is the adjustment of behaviour
in response to a perceived reduction in risk, a critical
issue in the public health implementation of PrEP
because of the potential for increased risky sexual
behaviour which could counteract biological effi-
cacy [1]. Placebo-controlled randomized trials are
regarded as the gold standard for establishing the
biological efficacy of an experimental drug. A key
rationale for using placebo in trials of PrEP agents
has been to avoid bias because of differential
exposure to HIV caused by different sexual behav-
iour in the randomized groups; this contrasts with © 2015 Wolters Kluwerthe real-life situation, where individuals know if
they are taking an active drug. A frequently unap-
preciated point is that risk compensation cannot be
assessed by standard within or between group com-
parisons in a placebo-controlled trial [2]. The Euro-
peanMedicines Agency stated that ‘The behavioural
impact of PrEP on risk compensation and condom
replacement cannot be assessed in prelicensure
placebo-controlled trials’ and that ‘it is mandatory
that the marketing authorisation application con-
tains a risk management plan that adequately covers
thepublichealth impactof thePrEP intervention’ [3].
In an imaginative analysis to gain insights into
risk compensation in the Preexposure ProphylaxisVolume 11  Number 1  January 2016
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KEY POINTS
 Open-label randomized trials are the only design that
can reliably assess risk compensation.
 The proportion of prevalent acute infections can
provide insights into underlying HIV incidence in the
trial population.
 New paradigms are required for noninferiority trials of
experimental PrEP regimens.
Issues in trials of preexposure prophylaxis Dunn and GliddenInitiative (iPrEx) trial, Marcus et al. [4] compared
patients who believed they were taking active drug
(n¼553) with patients who believed they were
taking placebo (n¼223). Patients who believed they
were receiving active drug had higher number of
receptive partners at baseline, but the difference
between the two groups did not increase during
follow-up after study drug was initiated. There
was also no difference at any time point in the
percentage of receptive anal intercourse partners
using condoms. These results were interpreted as
no evidence of risk compensation. However, this
study has several limitations: confidence intervals
were relatively wide (the analysis excludes 1429
patients who did not predict their treatment assign-
ment); the accuracy of self-reported data on sexual
practices; and the fact that groups were based on
perceived assignment rather than certain knowl-
edge as pertains in real-life. A further limitation is
that risk compensation is a function of how effective
an individual considers the intervention to be, and
the very high biological efficacy of tenofovir diso-
proxil fumarate/emtricitabine (TDF/FTC) was not
known at the time the study was conducted.
Grant et al. [5
&
] assessed and presented a detailed
analysis of a cohort studyofMSMenrolled from three
previous randomized controlled trials of PrEP
(including iPrEx) that were offered open-label PrEP.
The authors assessed risk compensation by looking at
longitudinal changes in behaviour, comparing pat-
terns amongmenwho accepted the offer of PrEP and
those who declined it. Self-reported total number of
sexualpartners, noncondomreceptive/ insertive anal
intercourse decreased during follow-up in both
groups and to a similar extent. Syphilis incidence
was also similar in the two groups. However, the fact
that the control groupwas not randomized limits the
interpretability of these data.
The most robust data on risk compensation to
date were obtained in PROUD, a pragmatic, open-
label trial which attempted to mimic how PrEP
would be administered in routine clinical practice
[6
&&
]. Eligible patients were randomized to receive1746-630X Copyright  2015 Wolters Kluwer Health, Inc. All rights rese
 Copyright © 2015 Wolters Kludaily TDF/FTC either immediately (n¼275) or after
a deferred period of 1 year (n¼269). Data from the
first year of follow-up allowed direct assessment of
risk compensation. Patients were asked to complete
monthly questionnaires and daily diaries about
sexual behaviour but the completion rates of these
were low, particularly in the deferred group. Accord-
ingly the investigators reported cross-sectional
analyses of sexual behaviour based on baseline
and 1 year questionnaires only. No differences were
found in terms of the total number of different anal
sex partners but there was marginal evidence of a
larger proportion of PrEP recipients at 1 year who
reported receptive anal sex with 10 or more partners
without a condom. An indirect, but more objective
measure of risky sexual behaviour, is the diagnosis of
other sexually transmitted infections (STIs) [7].
PROUD reported a slightly higher rate of diagnosis
with any bacterial STI in the immediate PrEP group
(57%) than in the deferred group (50%). However,
after adjustment for the number of screens, there
was no evidence of a difference between the groups
in the frequency of bacterial STIs, either individually
or overall.
A potentially important effect which could
impact negatively on the cost–effectiveness of PrEP
is that some men who have been using condoms
consistentlymay stop doing so because they are able
to access PrEP. Such men have not been eligible for
PrEP trials to date and are unlikely to be formally
eligible in PrEP implementation programmes. How-
ever, setting rigid criteria for PrEP access is not
realistic, and if this phenomenon is real it will be
difficult to detect it.Acute HIV infections at study enrolment
in the analysis
A clinical challenge with PrEP is the window period
between exposure to HIV and the (assay-dependent)
detection of infection, meaning that PrEP is inevi-
tably initiated in some individuals who are already
infected. The procedure used in most trials has been
to perform a point-of-care serological test for HIV on
the day of enrolment and to store an additional
plasma sample that is retrospectively tested for
HIV RNA, the earliest marker for HIV infection, if
the patient had a reactive HIV antibody test at their
first (or early) follow-up visit [8–12]. In real-life
clinical practice, procedures are usually less strin-
gent than in trials. United States guidelines recom-
mend ‘At aminimum, clinicians should document a
negative antibody test result within the week before
initiating (or reinitiating) PrEP medications’ [13].
Also, samples may not be routinely stored, preclud-
ing the possibility of retrospective testing.rved. www.co-hivandaids.com 117
wer Health, Inc. All rights reserved.
Table 1. Impact on effect measures of including or excluding patients with acute HIV infection at enrolment in the PROUD trial
ITT (all patients) Modified ITT (excluding acute cases)
Immediate Deferred Immediate Deferred
No. of infections 5 21 3 20
Follow-up (person-years) 243.5 222.1 243.5 222.1
Incidence rate 2.1 9.5 1.2 9.0
Rate difference 7.4 7.8
Number needed to treat 13.5 12.9
Efficacy (%) 78 86
Three patients (two Immediate, one Deferred) tested nonreactive by a third-generation rapid test on the day of enrolment but reactive with a joint antigen/antibody
assay. ITT, intention to treat.
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FIGURE 1. Proportion of patients with acute infection at
enrolment plotted against incidence of infection observed in
placebo recipients. Limited to studies that tested enrolment
plasma samples retrospectively for HIV RNA. Value in
brackets is number of acute infections observed in each
study. The inferred incidence of infection at enrolment
(plotted on right-hand vertical axis) was estimated by
dividing the proportion of patients who were HIV RNA-
positive/antibody negative by the mean interval between the
detection of HIV RNA and antibody [20]. We assumed a
value of 15.1 days using data from Eller et al. [21].
The PrEP revolution: from clinical trials to routine practiceThe primary efficacy analyses of trials have
generally excluded patients with detectable HIV
RNA at enrolment [modified intention-to-treat,
(mITT)] on the grounds that PrEP cannot possibly
avert infection in these individuals. (PrEP may have
a postexposure prophylaxis effect but only if
initiated within 48–72h of exposure.) From an
effectiveness rather than an efficacy perspective a
full ITT analysis including all patients is arguably the
more relevant [14]. In particular, analyses of safety
outcomes should be intention-to-treat (ITT),
particularly those relating to drug resistance, as viral
mutations are particularly likely to emerge during
acute infection under selective drug pressure.
In practice, ITT and mITT analyses in most
studies produce very similar results as the number
of prevalent acute infections is generally much
smaller than the number of incident infections.
However, it canmake amaterial difference in studies
where adherence to PrEP is high. For example, of the
five infections in the immediate PrEP arm in
PROUD, two occurred at enrolment. Here, the esti-
mated efficacy is 78% under an ITT analysis com-
pared with 86% under an mITT analysis (Table 1).
Note that there is little effect on the rate difference
(or number-needed-to-treat), the most relevant
measure for public health.
Finally, in the following section we raise
the possibility of using the number of prevalent
acute infections (antibody negative/HIV RNA-
positive result on enrolment sample) to measure
the underlying ‘force of infection’ in the trial popu-
lation. The method is described in the footnote to
Fig. 1, which shows the inferred baseline incidence
plotted against the observed incidence of infection
among patients who were allocated to placebo in
trials that tested enrolment samples for HIV RNA.
With one exception, it over-estimates incidence is
overestimated by a factor of between 2 and 3. There
are two main possible explanations for this. First,
the calculation is highly sensitive to the assumption
about the mean interval between detectable118 www.co-hivandaids.com
 Copyright © 2015 Wolters Kluwer Hcirculating viral RNA and detectable circulating
antibody, which may be incorrect. Second, patients
may have been motivated to join the trial because
they had recently been at especially high risk of
exposure to HIV. Nonetheless, in large trials this
approach can provide a rough estimate of the under-
lying rate of infection.Future studies and the challenge of a highly-
efficacious control regimen
Although TDF/FTC is the only drug currently
approved by Food and Drug Administration for
prevention, there is a pipeline of other agents,Volume 11  Number 1  January 2016
ealth, Inc. All rights reserved.
Table 2. Outcomes in hypothetical study – low-incidence population
Group Total follow-up HIV infections Rate (per 1000 PY)
Effectiveness compared
to N (%) (95% CI)
Control (C) 5000 8 1.6 60 (5, 85)
Experimental (E) 5000 15 3.0 25 (54, 64)
No treatment (N) 5000 20 4.0 –
CI, confidence interval.
Issues in trials of preexposure prophylaxis Dunn and Gliddenparticularly long-acting agents [15]. Given the pro-
ven biological efficacy of TDF/FTC, there are ethical
barriers to conducting future clinical trials that
include a no PrEP comparison group. Possible excep-
tions to this are populations where PrEP is not policy
or where adherence to daily TDF/FTC is uncertain.
Donnell et al. comprehensively reviewed study
designs for PrEP interventions, assuming daily TDF/
FTC to be the control regimen [16
&&
]. They con-
sidered three different experimental regimens: a
new daily drug, a long-acting drug, and a different
TDF/FTC dosing strategy. For the first of these
scenarios, a noninferiority design would be the
natural choice. The study explored noninferiority
margins of 1.10, 1.20, and 1.25 on a hazard ratio
scale. For the highest noninferiority margin of 1.25,
and assuming the experimental intervention to be
equally effective to TDF/FTC, the authors show that
a trial would have to accumulate a total of 844 HIV
events to be sufficiently powered; this translates to a
sample size of approximately 19000 subjects for HIV
incidence of 2.25/100 person-years and 2 years fol-
low-up on average – an infeasible undertaking.
Further calculations were made under the
assumption that the experimental agent is more
effective than TDF/FTC, to enable smaller,
more realistic sample sizes. However, in the face
of strong evidence that TDF/FTC confers very high
protection if adequate drug concentrations are
achieved [17], this assumption is plausible only in
comparisons with long-acting drugs in a population
likely to experience barriers to adherence to a daily
oral medication.
The large number of required events for non-
inferiority studies is driven mainly by the use of the
hazard ratio (which is based on the multiplicative
scale) for assessing noninferiority. From a public
health perspective, the rate difference is the more
important metric as it translates directly to the
number needed to treat [18], and this concept can
be utilized in the comparison of drugs as well as to a
comparison of drug versus no treatment.
Suppose we did a clinical trial to compare an
experimental preventive intervention (E) to daily
TDF/FTC (control, C) in a group of 5000 volunteers.
The trial randomizes 2500/arm and follows them for1746-630X Copyright  2015 Wolters Kluwer Health, Inc. All rights rese
 Copyright © 2015 Wolters Klua total of 2 years, yielding the results in Table 2. The
HIV rate ratio (relative to C) is 1.88 [95% confidence
interval (CI) 0.74, 5.1]. Thus, the rate of HIV could
be as much as five times higher for E and would
clearly exceed any noninferiority margin. The rate
difference is much narrower: 1.4 (95% CI 0.4 to
3.3)/1000 person-years. For every thousand people
getting E rather thanC for 1 year, the best estimate is
that there would be 1.4 more infections (or 3.3 at
most).
We now argue that information on the number
of infections under the condition of no-treatment
(N) is essential context, noting this group is not
actually observed. Suppose, HIV incidence under
N is 4.0/1000 person-years. The effectiveness of E
compared to N is 25% (95% CI 54% to 64%) and
the effectiveness of C compared to N is 60%
(5–85%). It is helpful to compare the effectiveness
estimate for E and C on the additive scale:
6025%¼35% (95% CI 14 to 84%), which
represents that proportional increase in the number
of infections using E rather than C relative to the
number of infections in the absence of PrEP. Thus
given 5000 person-years follow-up we would expect
20 infections with no PrEP and 7 (15–8) more infec-
tions with the use of E rather than C (7/20¼35%);
this would seem to represent an appreciable loss
of efficacy.
Consider an alternative scenario where the trial
population is at 10 times higher risk of HIV and is
highly adherent to both E and C (Table 3). Under
this scenario, the effectiveness of E compared to N is
93% (95% CI 87–96%) and the effectiveness of C
compared to N is 96% (92–98%). The HIV rate ratio
is unchanged (1.88¼ (1–93%)/(1–96%)), but the
difference in effectiveness on the additive scale is
much smaller: 9693%¼3% (95% CI 1 to þ8%).
Given 5000 person-years follow-up, we still expect
seven more infections with the use of E rather than
C but this time against a background of 200 infec-
tions in the absence of PrEP. In this scenario,
E would seem to be an acceptable alternative to C.
The fact that underlyingHIV incidence as well as
adherence to PrEP can vary greatly between popu-
lations implies the need to anchor any comparison
to the number of HIV infection we would haverved. www.co-hivandaids.com 119
wer Health, Inc. All rights reserved.
Table 3. Outcomes in hypothetical study – high-incidence population
Group Total follow-up HIV infections Rate (per 1000 PY)
Effectiveness compared
to N (%) (95% CI)
Control (C) 5000 8 1.6 96 (92, 98)
Experimental (E) 5000 15 3.0 93 (87, 96)
No treatment (N) 5000 200 40.0 –
PY, person-years.
The PrEP revolution: from clinical trials to routine practiceobserved in the absence of PrEP. We propose, for
wider discussion, the use of a two-part noninferior-
ity definition:
(i) lElC<D and (ii) (lElC)/ lN< r,
where lE, lC, and lN are estimates of HIV incidence
in the E, C, and N groups respectively and the
noninferiority margins (D, r) are appropriately
chosen. (To simplify exposition, we have avoided
attaching probabilistic statements to the lower con-
fidence limits.)
For instance, in the low-incidence scenario the
upper CI for lElC is 3.3/1000 and the upper bound
on (lElC)/lN is 0.84 (or 84% more of total infec-
tions). In the high-incidence scenario, the upper CI
for lElC remains 3.3/1000 whereas the upper
bound on (lElC)/lN is now 0.08 (or 8% more of
total infections). The first part of the definition is
fully rigorous is the sense that it is intention-to-treat
and does not rely on an external estimate of lN, but
this is required for the second part of the definition.
The Partners Demonstration project estimated
this based on the placebo rate of HIV in the cohort
prior to the treatment period [19]. An alternative
approach could be to use the proportion of patients
with HIV RNA detected in their enrolment sample,
as described earlier. A final possibility is to
use external data in the population from which
the study patients are recruited, although this can
be misleading. The PROUD study observed an HIV
incidence of 9.0/100 person-years in the deferred
group, which was approximately seven-fold higher
than a national estimate of 1.34/100 person-years
for MSM attending sexual health clinics [6
&&
]; this
underscores that it may be difficult to assemble
control groups that accurately reflect the HIV risk
of individuals who seek participation in a trial.CONCLUSION
Placebo-controlled and open-label trials of PrEP
have addressed fundamentally different questions.
The former evaluates the biological efficacy of the
PrEP agent studied; the latter attempts to evaluate
real-life effectiveness, reflecting the impact of risk120 www.co-hivandaids.com
 Copyright © 2015 Wolters Kluwercompensation and actual adherence. Future trials of
PrEP are highly challenging to design since daily
TDF/FTC, the natural control regimen, is highly
efficacious. New statistical paradigms for noninfer-
iority trials are required, with statisticians and
expert clinicians working closely together to develop
these.
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